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Potency and stability of C terminal truncated
human epidermal growth factor
D P Calnan, A Fagbemi, J Berlanga-Acosta, T Marchbank, T Sizer, K Lakhoo,
A D Edwards, R J Playford
Abstract
Introduction—Epidermal growth factor
(EGF) is normally present as EGF1–53. A
variety of C terminal truncated forms
have been used in preliminary trials for
treating gastrointestinal injury but their
relative potency and stability when used in
a clinical setting are unclear. Therefore,
we compared the biological activity of
recombinant EGF1–53, EGF1–52, EGF1–51, and
the C terminal peptides EGF44–53 and
EGF49–53.
Methods—Purity of forms was confirmed
by mass spectrometry. Bioactivity of the
diVerent EGF forms was determined
using [methyl-3H] thymidine incorpora-
tion into primary rat hepatocytes and
their ability to reduce indomethacin
(20 mg/kg subcutaneously)/restraint in-
duced gastric injury in rats. Stability of
EGF peptides was determined by serial
sampling from a syringe driver system
containing EGF/4% albumin in saline.
Results—Biological activity assays of
EGF1–53, EGF1–52, and EGF1–51 gave almost
identical thymidine uptake dose-response
curves (maximal responses increasing
baseline uptake from 4400 (600) cpm
(mean (SEM)) to about 22 000 (2000) cpm
when EGF was added at 1.6 nM). EGF44–53
and EGF49–53 did not stimulate
3H thymi-
dine uptake. Control rats had 47 (4) mm2
damage/stomach, EGF1–51, EGF1–52, and
EGF1–53 at 0.16 and 0.80 nmol/kg/h each
reduced gastric injury by about 50% and
80%, respectively (both doses p<0.01 com-
pared with control but no significant
diVerence between the diVerent forms).
EGF was stable at room temperature for
seven days but biological activity de-
creased by 35% and 40% at two and three
weeks, respectively (both p<0.01). Expo-
sure to light did not aVect bioactivity.
Conclusion—EGF1–51 and EGF1–52 are as
biologically active as full length EGF1–53
but the C terminal penta- and decapep-
tides are ineVective. Clinical trials of EGF
can probably use infusion systems for at
least 48 hours at room temperature and
with exposure to light, without reducing
biological eYcacy.
(Gut 2000;47:622–627)
Keywords: epidermal growth factor; intestinal injury;
nutrition
Epidermal growth factor (EGF) is secreted
into the gastrointestinal lumen by the salivary
glands and the Brunner’s glands of the
duodenum.1 It is initially produced as a 1207
amino acid precursor2 which is subsequently
processed to the “mature” EGF1–53 form which
includes three intrachain cysteine (Cys)-Cys
double bonds. It is likely that the major source
of EGF present in the gastric juice is derived
from swallowed saliva. Although EGF1–53 is
generally considered to be the “mature” form
of EGF in humans, C terminal truncated forms
occur naturally as a result of partial cleavage by
proteases present in the gastric juice, mainly to
EGF1–49
3 and in plasma to EGF1–52.
4 In addition
to these smaller forms of EGF, higher molecu-
lar weight forms are also found in human urine,
probably derived directly from the kidney.5
EGF is a potent stimulant of proliferation
and healing in vitro and in animal models in
vivo. There is therefore much interest in the
potential clinical applications of recombinant
EGF for the treatment of gastrointestinal dam-
age, particularly in relation to small and large
intestinal disease where present therapies are
suboptimal. Preliminary human trials of EGF
for conditions such as neonatal necrotising
enterocolitis and microvillus atrophy have pro-
vided encouraging results. However, there has
been inconsistency in the form of EGF used,
with various clinical trials using EGF1–48, a
mixture of EGF1–51 and EGF1–52, or EGF1–53
alone.6–11 As the potency of the EGF molecule
is highly dependent on the C terminal
residues,3 12 13 it is diYcult to extrapolate the
equivalent dosage (in terms of biological activ-
ity) from one trial to another.
We are aware of only one commercial prod-
uct of EGF which is currently available for
clinical use in an intravenous formulation
(HeberBiotc SA, Havana, Cuba). This com-
prises a 60:40 mixture of EGF1–51 and EGF1–52.
However, there are limited data on the relative
biological potency of these EGF1–51 and EGF1–52
forms compared with the full length EGF1–53.
Hence we purified the separate forms of
EGF and compared their biological potency
with the full length molecule. In addition, as
much of the biological activity of EGF appears
to be dependent on the C terminal amino
acids, we also examined the biological activity
of synthetic peptides coding for the C terminal
penta- and decapeptides of the EGF molecule.
EGF has a short circulating half life (about
eight minutes) and most clinical studies there-
fore use a continuous intravenous protocol (for
Abbreviations used in this paper: Cys, cysteine
(residues); EGF, epidermal growth factor; HPLC, high
pressure liquid chromatography; TFA, trifluoroacetic
acid.
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example, see Sullivan and colleagues8). How-
ever, the stability of EGF, in terms of
maintenance of biological activity while
present in the infusion system (usually at room
temperature), has not been fully addressed. In
addition, these neonates receiving EGF for
necrotising enterocolitis or congenital microvil-
lus atrophy are also likely to be treated with
phototherapy to reduce the risk of kernicterus.
However, the eVect of exposure to light on the
biological activity of EGF has not been exam-
ined. Hence we also determined the
importance of these factors on the biological
activity of the EGF preparation which is avail-
able for clinical use (that is, the EGF1–51/
EGF1–52 mixture).
Materials and methods
Human recombinant EGF1–51 and EGF1–52
mixture, expressed in Saccharomyces cerevisiae,
was obtained from Heber Biotc SA (Havana,
Cuba). This product is >95% pure as assessed
by high pressure liquid chromatography
(HPLC). Full length EGF1–53 expressed in
E coli was purchased from Promega UK Ltd
(Southampton, UK) and is >95% pure, as
assessed by HPLC. Cell culture media and
reagents were obtained from Gibco, Life Tech-
nologies Ltd (Paisley, Scotland, UK). [Methyl-
3H] thymidine was obtained from Amersham
Life Science (Little Chalfont, UK). All other
reagents were obtained from Sigma-Aldrich
Company Ltd (Poole, Dorset, UK).
SEPARATION OF THE DIFFERENT FORMS OF EGF
EGF1–51 and EGF1–52 were purified from the
commercially available recombinant mixture
using reverse phase HPLC. In addition, to
ensure consistency between the sample prepa-
rations, EGF1–53 was treated in a similar way.
The system used for these studies comprised
the Hewlett Packard (Stockport, UK) 1100
consisting of a quaternary pump delivery
system, Rheodyne-7725 sample injector, and
200 µl injection loop. Samples were collected
on a Foxy-Jr fraction collector and the system
was controlled by a HP pentium PC with HP
Chemstation software. The column used was
an analytical “Jupiter” C5, 300 Å, 5 µm
(4.6×150 mm) column (Phenomenex UK Ltd)
with a 0.1% trifluoroacetic acid (TFA)/
acetonitrile gradient. Peptide peaks were iden-
tified by UV detection at a wavelength of
280 nm.
Purified fractions were collected, lyophilised,
and protein concentration determined using a
commercial, modified Lowry based, calorimet-
ric microplate assay with human albumin as
standard (Bio-Rad Laboratories Ltd, Hercules,
California, USA).
The identity of each form was determined by
assessment of molecular weight using the tech-
nique of matrix assisted laser desorption time
of flight with a Finnigan LaserMAT mass spec-
trophotometer (San Jose, California, USA).
Samples were mixed with 0.5 µl of alpha-
cyano-4-hydroxycinnamic acid matrix (1% in
50% acetonitrile, 0.1% TFA). Standards used
were oxidised insulin â chain (molecular
weight 3496.9) and ubiquitin (molecular
weight 8564.9). This technique has been
validated previously for use in peptide se-
quence analyses.3–14
SYNTHESIS OF PENTA- AND DECAPEPTIDES
Peptides corresponding to the last five and 10
C terminal amino acids of human EGF were
obtained from the Peptide Synthesis Labora-
tory (Imperial Cancer Research Fund, Lon-
don, UK). They were synthesised on a 431A
PE Biosystems peptide synthesiser and ana-
lysed for purity using reverse phase HPLC and
mass spectrometry, as detailed above. The
amino acid sequences of the two peptides were:
pentapeptide—NH2 Trp-Trp-Glu-Leu-Arg
COOH and decapeptide—NH2 Tyr-Arg-Asp-
Leu-Lys-Trp-Trp-Glu-Leu-Arg COOH.
ASSAY OF BIOLOGICAL ACTIVITY OF DIFFERENT
FORMS OF EGF IN VITRO
Background
Primary rat hepatocytes provide a robust
reproducible method for determining the
biological activity of EGF-like molecules. We
have previously used this method to determine
the biological activity of other truncated forms
of EGF.3 The methodology is therefore de-
scribed only briefly below.
Preparation of primary rat hepatocytes
Male August rats were anaesthetised with
Hypnorm (Janssen-Cilag Ltd, High Wycombe,
UK) and hepatocytes were isolated by in situ
collagenase perfusion. The basic protocol con-
sists of a two step perfusion of the liver in situ
via the portal vein, first with calcium free buVer
followed by a calcium supplemented buVer
containing collagenase.
The digested liver was removed, cells dis-
persed, filtered and centrifuged, and re-
suspended in a plating medium. For all studies,
hepatocytes were grown in Williams E medium
without L-glutamine (Gibco BRL, Paisley,
Scotland, UK) containing 5% fetal calf serum.
Cell viability, determined by the ability to
exclude 0.2% trypan blue, was greater than
80% in all experiments.
Assay protocol
The various purified forms of EGF, the
commercial mixed EGF1–51/EGF1–52 prepara-
tion, and the C terminal peptides were added
to the wells. Twelve hours later, [methyl-3H]
thymidine (0.8 µM, 20 µCi/ml) was added to
the wells and the plates incubated for a further
18 hours. [Methyl-3H] thymidine incorpora-
tion into TCA precipitated material was deter-
mined by liquid scintillation using a 1450
Microbeta Trilux plate reader (EG&G Wallac,
Turku, Finland). Each condition was examined
in at least four separate wells during each study
and was also examined on three separate occa-
sions.
As a preliminary study, dose-response curves
to the diVerent forms of EGF were performed
in the presence and absence of dexamethasone
10−8M and insulin 10−7M. This was done
because it has been reported that dexametha-
sone improves cell plating eYciency and
insulin enhances the stimulatory eVect of
Potency of C terminal truncated EGF 623
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EGF.15 Although the shape of the dose-
response curves were virtually identical in the
presence or absence of dexamethasone/insulin,
the baseline/stimulated [methyl-3H] thymidine
ratios were higher when these were added.
Dexamethasone and insulin were therefore
always used in subsequent studies.
ASSAY OF BIOLOGICAL ACTIVITY OF DIFFERENT
FORMS OF EGF IN VIVO
The ability of EGF to prevent gastric damage
by indomethacin and restraint in rats was
assessed using previously validated methods.3
Under light ether anaesthesia, rats (male
Sprague Dawley, 225–250 g) had two sub-
cutaneous cannula inserted into the back of the
neck and were then placed in Bullman restraint
cages. When the animals had recovered, a con-
tinuous subcutaneous infusion of saline or the
various doses and forms of EGF or C terminal
peptides was started at 1 ml/h, using a multi-
syringe infusion pump (Harvard Apparatus,
Massachusetts, USA). EGF1–53, EGF1–52, and
EGF1–51 were infused at 0.16 and 0.80
nmol/kg/h whereas much higher doses (up to
63 nmol/kg/h) were used for the short peptides.
This decision was based on the fact that our in
vitro studies suggested that all three long forms
of EGF were likely to have similar biological
eYcacy and we have previously shown a good
dose-response for EGF1–53 when used at these
doses.3 In contrast, the in vitro studies
suggested much higher doses of the penta- and
decapeptides would be required to elicit any
biological activity. Thirty minutes later,
20 mg/kg of indomethacin were injected
subcutaneously via the second cannulae. The
animals were killed by stunning and cervical
dislocation three hours later and their stom-
achs removed and inflated with 4 ml of 10%
formalin. The next day the stomachs were
opened and placed in fresh formalin prior to
assessment. The stomachs were randomly
coded and all analyses of gastric damage were
assessed blind. Total ulcerated area (mm2/
stomach) was assessed using a dissecting
microscope (×10) with the aid of a square grid.
The stomachs were then embedded in wax and
the depth of damage assessed microscopically
and given a microscopic ulcer score, as
previously described.16 Using this system, each
stomach was given a score of 0–4 (0, no dam-
age; 1, one small erosion (less than 0.5 mm); 2,
two small or one large erosion (greater than 0.5
mm); 3, two or more large erosions; and 4, any
area of ulceration extending to the muscularis
mucosa).
STABILITY OF EGF SOLUTIONS IN A CLINICAL
SETTING
To reproduce likely clinical conditions, the
commercially available EGF1–51/EGF1–52 mix-
ture was diluted to a concentration of 1 µg/ml
in a 4.5% solution of human albumin (to mini-
mise adhesion of peptide to the infusion
system) and split into two samples. The test
solutions were pumped at room temperature
(24–26°C) through an infusion system com-
prising a syringe driver and a 50 ml syringe
attached to a paediatric infusion system (“giv-
ing set”, IVAC G30402). Sample aliquots
(2 ml) were taken from the distal end of the
infusion system at regular intervals up to 21
days and immediately frozen and stored at
−20°C until subsequent assay. One infusion
system was covered in silver foil (“dark”) and
the other was placed under a single 4-tube
Medical Phototherapy Unit lamp (Vickers plc,
UK) at a distance of 50 cm, for the duration of
the experiment (“light”). This was to mimic
the conditions of phototherapy treatment com-
monly prescribed for the jaundiced neonate.
Samples were subsequently analysed for bio-
logical activity using the rat hepatocyte assay
described above.
STATISTICS
Data were analysed using ANOVA. For all
analyses, if a significant eVect was found
(p<0.05), individual comparisons were per-
formed using t tests based on the residual and
degrees of freedom obtained from the ANOVA,
a method equivalent to repeated measures
analysis.
Results
The diVerent forms of EGF eluted from the col-
umn as single peaks at 39 minutes (EGF1–53), 40
minutes (EGF1–52), and 43 minutes (EGF1–51).
Analyses by mass spectrometry gave molecular
masses close to calculated theoretical values:
EGF1–53: 6222 versus 6222 calculated; EGF1–52:
6104 versus 6109 calculated; EGF1–51: 5950 ver-
sus 5953 calculated.
IN VITRO ASSAY
Each form of EGF gave virtually identical maxi-
mal responses with a sixfold increase in [methyl-
3H] thymidine uptake above baseline values (all
p<0.001 v baseline values) when added at 1.6
nM. Baseline values were 4400 (600) cpm
(mean (SEM)) and increased to 22 100 (4300)
in response to EGF1–53, 22 100 (1000) in
response to EGF1–52, 24 700 (3200) in response
to EGF1–51, and 22 800 (2000) in response to the
commercial mixed forms (eVect of form, p=0.80
on ANOVA). Dose-response curves were also
virtually superimposable (fig 1) and ANOVA
showed no diVerence in response due to
diVerent forms (eVect of form p=0.33 on
ANOVA). Addition of the deca- or pentapeptide
Figure 1 EVect of epidermal growth factors EGF1–53,
EGF1–52, and EGF1–51 on [methyl-
3H] thymidine uptake
into primary rat hepatocytes. The dose-response curves of
the various forms of EGF are virtually superimposable.
Results are expressed as mean (SEM), n=4.
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at doses up to 100 ng/ml (127 nM for pentapep-
tide and 68 nM for decapeptide) did not stimu-
late [methyl-3H] thymidine uptake above base-
line values (data not shown).
IN VIVO ASSAY
Control rats had 47 (4) mm2 damage/stomach.
Administration of EGF1–51, EGF1–52, and
EGF1–53, each given at 0.16 and 0.80 nmol/kg/h,
reduced gastric injury by about 50% and 80%,
respectively (both doses p<0.01 v control but no
significant diVerence between forms) (fig 2A).
Assessment using the microscopic scoring sys-
tem gave similar results (fig 2B). The penta- and
decapeptides showed no protective eVects when
infused up to doses of 50 µg/kg/h (63 and 34
nmol/kg/h, respectively, data not shown).
STABILITY OF INFUSION SOLUTION OF EGF
Under both “light” and “dark” conditions,
EGF was stable at room temperature for seven
days but biological activity decreased by about
20–30% at two weeks and by 35–40% at three
weeks (both p<0.05 v initial levels) (fig 3).
Exposure to light did not aVect bioactivity
(p=0.06 on ANOVA).
Discussion
We used two well validated in vitro and in vivo
models to compare directly the biological
activity of EGF derivatives. In both systems,
EGF1–51, EGF1–52, and EGF1–53 had similar
potencies whereas the C terminal penta- and
decapeptides were inactive. Stability studies
showed that solutions of EGF were stable for at
least 48 hours at room temperature and with
exposure to light, without any reduction in bio-
logical eYcacy.
For the in vitro studies, we used the rat
hepatocyte system as it provides a robust,
reproducible model for examining growth fac-
tor activity and we have previous experience of
its reliability in assessing the biological activity
of other EGF derivatives.3 It provides a highly
reproducible dose-response curve and is of
particular value for examining growth factor
activity in intestinal juice as hepatocytes are not
adversely aVected by normal small intestinal
luminal contents.17 This assay system has the
advantages of using primary cells of gastro-
intestinal origin and providing a steep dose-
response curve. This latter point is particularly
relevant if comparing molecules which have
similar potency. It cannot be used, however, to
assess changes in cell number as under the
conditions used, hepatocytes complete cell
DNA synthesis but cell division occurs infre-
quently and no net increase in cell number is
seen.15 Other assays which allow assessment of
change in cell number have the limitation of
Figure 2 Comparison of the biological activity of various
forms of epidermal growth factor (EGF) using attenuation
of gastric damage as a bioassay. Rats were restrained and
given a continuous subcutaneous infusion of saline
(control), EGF1–53, EGF1–52, or EGF1–51. Thirty minutes
later, all animals also received indomethacin (20 mg/kg
subcutaneously). Three hours after administration of
indomethacin, all animals were killed and the amount of
gastric injury assessed. (A) All forms of EGF reduced the
amount of total ulcerated area (mm2/stomach) (all p<0.01
v control) but there were no diVerences in potency between
the forms. (B) Assessment using a microscopic damage
score, where each stomach was given a score of 0–4 (0, no
damage; 1, one small erosion (less than 0.5 mm); 2, two
small or one large erosion (greater than 0.5 mm); 3, two or
more large erosions; and 4, any area of ulceration extending
to the muscularis mucosa). Results are expressed as mean
(SEM), n=6 animals per datum point.
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placed in a clinical setting.A 60:40 mixture of EGF1–51 and
EGF1–52 is commercially available in an intravenous
formulation.To determine its stability under likely clinical
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1 µg/ml in a 4.5% solution of human albumin and divided
into two samples. The test solutions were pumped at room
temperature (24–26°C) through an infusion system.One
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placed under a phototherapy lamp to mimic the conditions of
phototherapy treatment commonly prescribed for the
jaundiced neonate. Samples were subsequently analysed for
biological activity using the rat hepatocyte assay.Results are
expressed as mean (SEM), n=4.
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poor dose-response curves and use malignant
cell lines or cells of limited relevance to the
gastrointestinal tract (for example, 3T3 fibro-
blasts).
EGF has many eVects, including stimulation
of cytoprotection, mucus production, and cell
migration. Some workers have used inhibition
of acid secretion as a marker of biological
activity of C truncated EGF derivatives. The
physiological relevance of luminal EGF in con-
trolling acid secretion is, however, unclear as it
is unlikely to reach its receptor under non-
damaged circumstances.18 In addition, there is
little consistency in results from studies exam-
ining the eVect of C terminal truncation of
EGF on acid secretion; Hollenberg and
Gregory found that EGF1–47 had no loss of bio-
logical activity compared with EGF1–53 in terms
of acid inhibitory activity, despite a 10-fold loss
of ability to incorporate 3H thymidine into
fibroblasts.19 In contrast, Gregory and
coworkers found that EGF1–47 had only an
eighth of the activity of the intact molecule in a
similar assay.12 We therefore decided to use a
cytoprotection assay for the in vivo studies.
There are many well validated acute models
of gastric injury. We chose the indomethacin/
restraint model as our in vivo assay system
because peptic ulceration due to non-steroidal
anti-inflammatory drugs is a major source of
morbidity and mortality in humans20 and we
have previously used it to examine the
influence of peptic digestion on the EGF
molecule.3 Results from the in vitro and in vivo
models gave consistent results in that all three
forms of EGF gave similar dose-responses
whereas the C terminal peptides were without
biological eVect.
EGF is produced as a 1207 amino acid
precursor2 and is subsequently processed to the
mature 53 amino acid form. In addition to the
salivary glands, gastrointestinal EGF is also
produced by the Brunner’s glands of the
duodenum and the ulcer associated cell
lineage—a recently identified glandular struc-
ture induced at sites of injury. Its concentration
in gastric juice is about 500 ng/l3 21 with urine
concentrations being about one tenth of those
found in gastric juice.22 Circulating levels of
EGF are extremely low and probably consist
mainly of the EGF1–52 form
4 with much of this
circulating EGF being bound to platelets. Early
studies on the stability of EGF within the
gastrointestinal lumen reported that EGF1–53
was stable in acid and pepsin, but we have sub-
sequently shown that it is cleaved to EGF1–49
(and to a lesser extent EGF1–46) in acidic gastric
juice in vitro and in vivo.3 EGF is also suscepti-
ble to digestion by pancreatic proteases within
the small intestinal lumen.17 The major site of
EGF production outside of the gastrointestinal
tract is the kidney where much larger forms of
EGF are produced (molecular weight approxi-
mately 30 000) and excreted into urine.5
It is now generally accepted that the C
terminal amino acids of the EGF molecule play
a key role in mediating much of its biological
activity. Loss of the C terminal seven (EGF1–46)
amino acids results in at least 80–90%
reduction in the potency of the ligand to bind
in receptor binding studies,12 with site directed
mutagenesis studies showing that the leucine
residue at position 47 is of particular
importance in maintaining biological activity.23
We have previously shown that loss of the
terminal five (EGF1–48) or four (EGF1–49) amino
acids also has a marked eVect on biological
activity, their potency being only about 25–
30% of EGF1–53 as assessed using in vitro and in
vivo systems.3 13 Although less well studied,
EGF1–50 also has reduced biological activity,
having about 50% of the activity of EGF1–53, as
assessed by [3H] thymidine uptake into 3T3
fibroblasts.12
There have been only limited studies exam-
ining the importance of the final two C termi-
nal amino acids of the EGF molecule in medi-
ating biological activity. Araki and coworkers
reported a 4% and 10% reduction in the bind-
ing aYnities of EGF1–51 and EGF1–52 to KB
cells.4 However, in vivo studies were not
performed. Our results therefore support the
idea that the terminal two amino acids do not
play a key role in mediating the biological
eVects of EGF and extend previous findings by
showing that this is also true when a patho-
physiologically relevant in vivo model is used.
This is an important point as diVerences in
functional biological activity due to factors
such as the systemic handling of the various
peptides (for example, circulating t1/2) would
not have been apparent from in vitro studies.
Conversely, the results of the in vitro assay
strongly suggest that the lack of activity of the
penta- and decapeptides was not due to rapid
excretion in vivo. Formal pharmacokinetic
studies would be of interest but are compli-
cated by the fact that the immunoreactivity of
the diVerent forms of EGF varies3 and that
standard size exclusion column separation
techniques of radiolabelled EGF are too insen-
sitive to detect minor clipping of the EGF
molecule.3 Analysis of the circulating form(s)
and bioactivity of EGF in vivo is therefore dif-
ficult to achieve.
As stated previously, the importance of the C
terminal seven amino acids in mediating
biological responses is well demonstrated by
the fact that most of the biological activity of
EGF is lost if EGF1–46 is used.
12 However, it is
also apparent that the intrinsic biological activ-
ity of the EGF molecule requires additional
areas of sequence, as shown by our findings
that the penta- and decapeptides were inactive.
Identification of which residues outside of the
C terminal region of the EGF molecule are
vital for biological activity is diYcult and
complex.24 Part of this complexity results from
the fact that, in common with many other bio-
logically active peptides, Cys-Cys disulphide
bridging within the EGF molecule brings
amino acid residues which appear distant on
the primary sequence into close proximity in its
correctly folded tertiary state.
Recombinant peptides are being increasingly
used for a variety of clinical conditions. Exam-
ples include recombinant human insulin for
the treatment of diabetes, erythropoietin for
renal failure induced anaemia, and interferon
for viral hepatitis. The use of recombinant pep-
626 Calnan, Fagbemi, Berlanga-Acosta, et al
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tides for “hollow organ” gastrointestinal condi-
tions is at a more preliminary stage although
early reports appear encouraging.25 EGF has
been advocated for a wide variety of gastro-
intestinal conditions, including necrotising
enterocolitis, congenital microvillus atrophy,
and inflammatory bowel disease. For all of
these conditions, data are only available from
limited clinical studies involving very few
patients, single case reports, or animal
experiments.6–9 26 Formal double blind, ran-
domised, controlled trials are planned by
several groups (personal communications) and
it is therefore important that researchers
appreciate the importance of consistency
regarding the forms/dosage of EGF to be used
(at least in terms of biological equivalence).
Our studies have shown that EGF is a robust
molecule, in terms of preservation of biological
activity, when used in a typical clinical setting.
Provided standard aseptic techniques are used,
infusions of EGF (with a carrier protein such as
albumin) can be continued for 24–48 hours in
the light without significant loss of activity,
minimising the time (and cost) required for its
usage.
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